Related Experiment Videos
Acquired craniofacial features associated with chronic phenytoin therapy
Clinical Pediatrics
|December 1, 1984
Summary
Phenytoin exposure during pregnancy can cause fetal abnormalities. This study highlights its underrecognized impact on postnatal facial structure, urging further research into this serious consequence.
Area of Science:
- Teratology
- Developmental Biology
- Clinical Genetics
Background:
- Phenytoin (diphenylhydantoin) is an anticonvulsant medication with known teratogenic effects.
- While fetal effects are documented, the long-term impact on postnatal facial development remains underemphasized.
Observation:
- Case histories and serial photographs of five individuals with mental retardation and unexplained dysmorphic features are presented.
- These individuals had a history of maternal phenytoin use during pregnancy.
Findings:
- The observed dysmorphic features suggest a pattern of craniofacial abnormalities linked to prenatal phenytoin exposure.
- These facial changes represent a serious, often overlooked, consequence of phenytoin therapy.
Implications:
- Increased awareness among clinicians regarding phenytoin's potential for causing postnatal facial dysmorphism is crucial.
- Further research is needed to determine the incidence, prevalence, pathogenic mechanisms, genetic predispositions, and critical developmental periods for these effects.